Autor(es): Ribeiro, Hugo ; Alves, Raquel ; Jorge, Joana ; Gonçalves, Ana Cristina ; Sarmento-Ribeiro, Ana Bela ; Veríssimo, Manuel T. ; Dourado, Marília ; Andrade, José Paulo
Data: 2023
Identificador Persistente: https://hdl.handle.net/10316/113982
Origem: Estudo Geral - Universidade de Coimbra
Projeto/bolsa: info:eu-repo/grantAgreement/FCT/6817 - DCRRNI ID/UIDB/PT;
Assunto(s): chronic pain; pharmacology; platelets; biomarkers; palliative care
Pain is one of the most frequent health problems, and its evaluation and therapeutic approach largely depend on patient self-report. When it is not possible to obtain a self-report, the therapeutic decision becomes more difficult and limited. This study aims to evaluate whether some membrane platelet proteins could be of value in pain characterization. To achieve this goal, we used 53 blood samples obtained from palliative patients, 44 with non-oncological pain and nine without pain. We observed in patients with pain a decrease in the percentage of platelets expressing CD36, CD49f, and CD61 and in the expression levels of CD49f and CD61 when compared with patients without pain. Besides that, an increase in the percentage of platelets expressing CD62p was observed in patients with pain. These results suggest that the levels of these platelet cluster differentiations (CDs) could have some value as pain biomarkers objectively since they are not dependent on the patient's participation. Likewise, CD40 seems to have some importance as a biomarker of moderate and/or severe pain. The identification of pain biomarkers such as CD40, CD49f, CD62p and CD61 can lead to an adjustment of the therapeutic strategy, contributing to a faster and more adequate control of pain and reduction in patient-associated suffering.
